New Data, New Opportunities, and New Clinical Challenges Using Immunotherapies for TNBC

Get up to date on the latest advances in immunotherapies for TNBC across multiple settings with expert commentaries, downloadable slides, and on-demand Webcast capturing a live CCO panel presentation.
Heather McArthur, MD, MPH
Program Director
Kevin Kalinsky, MD, MS
Heather McArthur, MD, MPH
Rita Nanda, MD

ClinicalThought

With pembrolizumab plus chemotherapy now approved for PD-L1–positive advanced TNBC, how can we leverage this regimen for treating patients with this challenging disease? Here’s my take.

Heather McArthur, MD, MPH Released: November 20, 2020

With sacituzumab govitecan, pembrolizumab, and atezolizumab all now approved for advanced TNBC, how do we sequence these agents and how does a BRCA1/2 mutation affect sequencing decisions? Here are my thoughts.

Kevin Kalinsky, MD, MS Released: December 23, 2020

Downloadable Slidesets

Download these slides for expert perspectives on incorporating immune checkpoint inhibitor–based therapy into optimal management of advanced/metastatic TNBC, including the biologic rationale, biomarkers for response, and key trial data.

Rita Nanda, MD Released: December 8, 2020

Download these slides for an expert-curated review of the latest developments in using immune checkpoint inhibitor–based therapy to treat early-stage TNBC, followed by insights into monitoring and management of immune-related adverse events.

Heather McArthur, MD, MPH Rita Nanda, MD Released: December 8, 2020

Download these slides for expert insights into approved and emerging antibody–drug conjugates for managing TNBC, including sacituzumab govitecan, ladiratuzumab vedotin, and more.

Kevin Kalinsky, MD, MS Released: December 8, 2020

Download this short summary slideset of key takeaways from a CCO live Webinar for an expert overview on incorporating immune checkpoint inhibitors and antibody–drug conjugates into optimal management of early-stage and advanced TNBC.

Kevin Kalinsky, MD, MS Heather McArthur, MD, MPH Rita Nanda, MD Released: December 16, 2020

On-Demand Webcast

In this interactive recording of a live CCO Webinar, a dynamic expert panel discusses the latest data on optimal use of immune checkpoint inhibitors and antibody–drug conjugates for treating patients with early-stage through metastatic TNBC.

Heather McArthur, MD, MPH
Program Director
Kevin Kalinsky, MD, MS Rita Nanda, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits ABIM MOC: maximum of 1.25 Medical Knowledge MOC point(s) Released: January 22, 2021 Expired: January 21, 2022
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Genentech, a member of the Roche Group
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue